Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633160 · ClinicalTrials.gov registry record · Phase 1
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
A Phase 1 study, sponsored by Clarity Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT05633160: Clinical Trial Phase 1 study, sponsored by Clarity Pharmaceuticals.
NCT05633160 is a Phase 1 study that was terminated before completion, run by Clarity Pharmaceuticals. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05633160, a Phase 1 study, was terminated before completion, sponsored by Clarity Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
Primary Outcome
MTD as determined by cohort observations of dose limiting toxicities or MFD determined by the activity of the dose to be administered, when the MTD has not been reached.
Interventions
- DRUG 64Cu-SAR-BBN
- DRUG 67Cu-SAR-BBN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 1 |
Why NCT05633160 stopped before completion
NCT05633160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which 64Cu-SAR-BBN is the first listed.
NCT05633160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05633160 about?
NCT05633160 is a clinical study titled "64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)". The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-expressing metastatic castrate resistant prostate cancer in patients who are ineligible for therapy with 177Lu-PSMA-617.
What is the current status of trial NCT05633160?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2023-06-15. Estimated completion is 2025-04-23.
What interventions are being tested in trial NCT05633160?
The interventions under investigation include: 64Cu-SAR-BBN (DRUG), 67Cu-SAR-BBN (DRUG).
Who is sponsoring clinical trial NCT05633160?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05633160's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI